top of page

AMH testing for fertility clinics: in-clinic draws, at-home kits and workflow

1 day ago
5 min read
Hand-drawn illustration of a finger-prick blood collection with an IHDLab at-home kit

Anti-Müllerian hormone (AMH) testing has moved from a specialist add-on to a routine part of fertility care. For clinics, the question today is less whether to order AMH and more how to fit it into the patient journey without adding visits, delays or confusion.


This guide covers why AMH became a first-line test, where at-home collection fits alongside venous draws, how to read an AMH report and what to ask a lab partner before offering kits. It's written for fertility clinics, women's health practices and telehealth programs, and it's educational only. Testing and treatment decisions belong with licensed clinicians.



Why AMH became a first-line test


AMH reflects the pool of small, growing follicles in the ovary, which makes it a practical marker of ovarian reserve and a standard part of fertility workups.


Current professional guidance supports that role. The ASRM committee opinion on ovarian reserve testing (2020) says AMH and antral follicle count (AFC) are the most sensitive and reliable ovarian reserve markers available. The 2025 ESHRE guideline on ovarian stimulation recommends AMH or AFC for predicting high and low response to stimulation. ASRM also stresses that ovarian reserve markers are poor predictors of reproductive potential independent of age.


Two features make AMH convenient operationally. It stays relatively stable across the menstrual cycle, so it doesn't need to be timed to cycle day 2 or 3. And it predicts oocyte yield well, which helps clinics plan stimulation.



What AMH can and can't tell a clinic


Clinics get the most from AMH when everyone on the team, and every patient, understands its limits.


  • AMH helps estimate how many eggs may be retrieved and the risk of low or high response to stimulation.

  • AMH doesn't measure egg quality and is only weakly associated with pregnancy and live birth, according to ASRM.

  • AMH doesn't predict natural fertility in people who haven't tried to conceive. A JAMA cohort study of women aged 30 to 44 found low AMH wasn't associated with lower chances of conceiving over 6 or 12 cycles.

  • ASRM advises against using ovarian reserve markers as a stand-alone fertility test, to promote planned egg freezing or to deny treatment.


For a deeper look at accuracy, assay differences and interpretation, see our guide: How reliable is AMH testing?



Where at-home AMH collection fits


Venous draws remain the default when a patient is already coming into the clinic. At-home finger-stick collection can remove a visit at points in the journey where a trip to a draw site causes friction:


  • Before a first consult, so the physician has an AMH result at the first appointment instead of ordering it there.

  • For patients who live far from the clinic or a draw site, or whose schedules make lab visits hard.

  • In telehealth fertility and women's health programs that don't have their own draw sites.

  • In employer or benefits-sponsored fertility programs where members are spread across many locations.


Evidence supports the approach when the method is properly validated. In a Human Reproduction validation study, matched dried blood spot and serum samples from 101 women showed strong agreement across the assay range. AMH in dried blood spots remained stable for 2 weeks at room temperature and 4 weeks refrigerated. That stability matters for kits that travel by mail. A 2026 paired-sample study found fingerstick and venous AMH highly correlated, but fingerstick values ran proportionally higher, so the authors advised against treating them as fully interchangeable without further validation. Each kit's method needs its own validation against venous serum.


Not every kit performs the same way, though. Collection quality, the assay used and how the lab reports results all affect whether a home result can sit next to a venous one in the chart.



Questions to ask a lab before offering AMH kits


  • How was the at-home method validated against venous serum, and against which assay?

  • Is the lab CLIA-certified, and in which states is it licensed to accept specimens?

  • What happens if a sample is insufficient or arrives damaged, and how is the patient recollected?

  • Which units and reference intervals appear on the report, and are they age-based?

  • Can results flow into your EMR or platform automatically, or only through a portal?

  • Can kits carry your clinic's brand, and who handles patient support questions?

  • Who is the ordering provider, and how are abnormal results escalated?



How to read an AMH report


Whether a sample was drawn in a clinic or collected at home, an AMH report usually includes the same elements. Teaching patients and staff to read them reduces follow-up calls.



The value and the unit


AMH is reported in ng/mL or pmol/L (1 ng/mL is roughly 7.14 pmol/L). Always check the unit before comparing a result with a chart or an earlier test.



The reference interval


Reference intervals vary by assay and often by age. A value should be read against the interval printed on that lab's report, not a generic chart found online. Results from different assays aren't directly interchangeable, so repeat tests are best run at the same lab.



Context the report can't show


The report won't show whether the patient uses hormonal contraception, which ASRM notes may lower AMH, or other clinical details. Capturing contraceptive use on the requisition or intake form helps the reviewing clinician interpret the number.



What the number means


In broad terms, low-for-age AMH suggests diminished ovarian reserve and a smaller expected egg yield. Expected-for-age values suggest a typical response to stimulation is likely. High-for-age values can point to a strong response and are sometimes seen with polycystic ovary syndrome (PCOS). None of these on its own diagnoses infertility or predicts pregnancy, so patients should review results with a clinician.



Designing the workflow


A simple AMH workflow for a clinic or telehealth program looks like this:


  1. The clinician orders AMH, as a venous draw or an at-home kit, based on where the patient is in the journey.

  2. Kits ship directly to the patient with clear collection instructions and a prepaid return.

  3. The lab receives and runs the sample and reports results with units, the assay and age-based intervals.

  4. Results route to the EMR or platform and are flagged for clinician review.

  5. The patient receives a plain-language summary and a follow-up visit or message from the care team.


Track kit return rates, recollection rates and time from order to result. These show quickly whether at-home AMH is saving visits or creating rework.



How IHDLab supports clinics with AMH


IHDLab is a CLIA-certified lab (CLIA 05D2040304) licensed in California, New York and Maryland, working only with clinics, telehealth platforms and health brands. Clinics can run AMH with their IVF bloodwork through our lab service, offer validated at-home AMH kits that ship anywhere in the US under IHDLab's name or their own, or combine both. Results can be delivered to your EMR, through our API or in a portal. Learn more on our fertility and IVF testing page, or see how we work with digital health partners.



Sources


bottom of page